Navigation Links
B. Braun Offers Wound Patients a New 'Over-the-Counter' Wound Management Gel - Prontosan®
Date:1/10/2011

BETHLEHEM, Pa., Jan. 10, 2011 /PRNewswire/ -- In its continued effort to advance best practices in wound care management, B. Braun Medical Inc. (B. Braun) announced today that Prontosan® Wound Management Gel with PHMB (Polyhexanide), a product used in the healthcare setting for cleaning wounds as well as moistening and lubricating absorbent wound dressings, is now available for over-the-counter (OTC) use. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Prontosan® Wound Management Gel for OTC use in November 2010.

(Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO)

"Effective wound care management no longer needs to be limited to within healthcare facility walls," said Mike Kelly, Director of Marketing, Infection Control Products for B. Braun Medical Inc. "The 510(k) clearance for over-the-counter use of Prontosan® Wound Management Gel advances B. Braun's commitment to infection prevention, helping to provide solutions that positively impact patients' care – in a physician's office, acute care setting or in a patient's home."

Prontosan® aids in the thorough removal of dirt and debris from chronic wounds, skin ulcers and abrasions, even when surfaces are difficult to access (i.e. skin folds, fissures and wound pockets), and can be used to cleanse and soften encrusted wound coatings.

The ready-to-use gel contains PHMB and Betaine, the surfactant for the cleansing and moistening of wounds. PHMB has quickly gained popularity among healthcare professionals as a wound irrigation cleanser. Its non-toxic and biocompatible formula offers ex
'/>"/>

SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. B. Braun Voluntarily Recalls Seven Lots of Heparin Manufactured in 2008 Due to Supplier-Initiated Recall of Heparin Active Pharmaceutical Ingredient (API)
2. B. Braun Wins Third Consecutive Safety IV Catheters Contract Award from Premier, Inc.
3. FDA-Approved Cefepime Now Available for Use in B. Brauns DUPLEX® System
4. B. Braun Customers Gain Premier Access to Zynx Health Device Networks Evidence-based, Customizable Drug Library Program
5. B. Braun Large Volume Heparin Infusion Solutions Now Available
6. New Technology Center Increases B. Brauns Infusion Pump Capacity
7. Health Robotics Re-Acquires CytoCares European Rights from B. Braun Melsungen AG for Undisclosed Consideration
8. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
9. B. Braun Renal Therapies Division Announces Availability of Adimea
10. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
11. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... that a new market research report is available in ... Drug Delivery System http://www.reportlinker.com/p0337136/Chinese-Markets-for--Drug-Delivery-System.html ... System has grown at a fast pace in the ... and demand will continue to grow. This new study ...
... 9, 2010 Reportlinker.com announces that ... catalogue: Prostate Cancer - Italy Drug ... http://www.reportlinker.com/p0332355/Prostate-Cancer---Italy-Drug-Forecasts-and-Treatment-Analysis-to-2020.html Prostate Cancer - Italy ... SummaryGlobalData,s pharmaceutical report, "Prostate Cancer - Italy Drug ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Drug Delivery System 2Reportlinker Adds Chinese Markets for Drug Delivery System 3Reportlinker Adds Chinese Markets for Drug Delivery System 4Reportlinker Adds Chinese Markets for Drug Delivery System 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 14
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... 2014 “ SmileStix ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... stickers. , The old saying goes, “A picture says a ... that can describe a single image, because each picture holds ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... that acupuncture provided significant reductions in pain, dysfunction, and ... neck dissection. The study was led by David Pfister, ... Service, and Barrie Cassileth, PhD, Chief of the Integrative ... Pfister presented the findings today at the annual meeting ...
... Phase II studies demonstrated potential for pazopanib as a single,agent treatment for ... -- In patients with stage I-III non-small cell lung cancer, 86 ... experienced a reduction in tumor volume ... overall response rate of 35 percent. The ...
... -- Leading oncologists and cancer researchers at NewYork-Presbyterian ... and clinical research findings at the 44th American ... Chicago, May 30 to June 3. , Highlights ... made by NewYork-Presbyterian/Weill Cornell physician-scientists include the following: ...
... to some experts, newly born neuronal stem cells in the ... if these stem cells are to be utilized in this ... be regulated. , A new study, led by Laurence ... University of the North Carolina School of Medicine, suggests a ...
... SCREENING FOR THE RISKS OF LIFE-THREATENING FALLS" ... strong connection between the cognitive function of their elderly ... , The study, which is in line with ... balance, also found a brief questionnaire designed to probe ...
... American,Physicians, Inc. (CAP) today announced that the exceptional financial,strength ... again,earned an A+ rating from A.M. Best Company, a ... year that MPT has,achieved this rating., "We are ... again this year,",said CEO James L. Weidner. "It validates ...
Cached Medicine News:Health News:Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 2Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 3Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 4Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2
... laboratories that have decided to change to the ... the RELISA ANAs correlation with IFA and many ... competition. While no ELISA ANA currently on the ... our RELISA ANA screen has been shown to ...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... Indirect Fluorescence Assay (IFA) for Anti-native ... for the qualitative and semi-quantitative detection ... nDNA in human serum. Detection of ... be used as an aid in ...
Medicine Products: